For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 7,585 | |||
| Impairment of long-lived assets | 854 | |||
| Total operating expenses | 8,439 | |||
| Operating loss | -8,439 | |||
| Non-cash (loss) gain on changes in fair value of warrant liability | 24,486 | |||
| Accretion of interest and amortization of discounts on convertible notes | 277 | |||
| Other expense, net | -20 | |||
| Net loss from continuing operations | -33,222 | |||
| Net income from discontinued operations, net of taxes | 11,081 | |||
| Net loss | -22,141 | |||
| Less increase to accumulated deficit due to adjustment to common stock warrant exercise price | 0 | |||
| Less increase to accumulated deficit due to adjustment to preferred stock conversion price | 0 | |||
| Net loss attributable to common stockholders | -22,141 | |||
| Basic EPS | -3.8 | |||
| Basic Average Shares | 5,820,000 | |||
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)